📊 IMUX Key Takeaways
Is IMUX a Good Investment? Thesis Analysis
IMMUNIC exhibits severe financial distress with negative stockholders' equity of -$6.7M, indicating technical insolvency. The company is burning $85.8M annually in operating cash while generating only $22K in revenue, leaving approximately 2 months of cash runway at current burn rates. Immediate capital raise or dramatic revenue inflection is required for survival.
Why Buy IMUX? Key Strengths
- Maintains $15.5M in cash providing near-term liquidity buffer
- Gross margin of 40.9% indicates viable unit economics if revenue scales
- Biotech sector exposure offers potential for transformative value if pipeline succeeds
IMUX Investment Risks to Consider
- Negative stockholders' equity of -$6.7M represents technical insolvency
- Unsustainable cash burn: $85.8M operating cash flow deficit with $15.5M cash = ~2 month runway
- Minimal revenue generation ($22K) against $103.2M operating losses indicates pre-revenue stage dependency
- Current ratio of 0.75x signals immediate liquidity stress and inability to meet short-term obligations
- No long-term debt structure suggests capital markets access may be severely constrained
Key Metrics to Watch
- Monthly cash burn rate and cash runway remaining
- Quarterly revenue growth and path to positive unit economics
- Occurrence and terms of any capital raises or financing events
- Operating cash flow trend and timing of operating cash flow inflection
IMUX Financial Metrics
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
IMUX Profitability Ratios
IMUX vs Healthcare Sector
How IMMUNIC, INC. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is IMUX Overvalued or Undervalued?
Based on fundamental analysis, IMMUNIC, INC. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
IMUX Balance Sheet & Liquidity
IMUX 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: IMMUNIC, INC.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.00 indicates the company is currently unprofitable.
IMUX Growth Metrics (YoY)
IMUX Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2014 | $22.0K | -$9.4M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
IMUX Capital Allocation
IMUX SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for IMMUNIC, INC. (CIK: 0001280776)
📋 Recent SEC Filings
❓ Frequently Asked Questions about IMUX
What is the AI rating for IMUX?
IMMUNIC, INC. (IMUX) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are IMUX's key strengths?
Claude: Maintains $15.5M in cash providing near-term liquidity buffer. Gross margin of 40.9% indicates viable unit economics if revenue scales.
What are the risks of investing in IMUX?
Claude: Negative stockholders' equity of -$6.7M represents technical insolvency. Unsustainable cash burn: $85.8M operating cash flow deficit with $15.5M cash = ~2 month runway.
What is IMUX's revenue and growth?
IMMUNIC, INC. reported revenue of $22.0K.
Does IMUX pay dividends?
IMMUNIC, INC. does not currently pay dividends.
Where can I find IMUX SEC filings?
Official SEC filings for IMMUNIC, INC. (CIK: 0001280776) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is IMUX's EPS?
IMMUNIC, INC. has a diluted EPS of $-0.62.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is IMUX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, IMMUNIC, INC. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is IMUX stock overvalued or undervalued?
Valuation metrics for IMUX: ROE of N/A (sector avg: 15%), net margin of -441,690.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy IMUX stock in 2026?
Our dual AI analysis gives IMMUNIC, INC. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is IMUX's free cash flow?
IMMUNIC, INC.'s operating cash flow is $-85.8M, with capital expenditures of $161.0K. FCF margin is -390,759.1%.
How does IMUX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -441,690.9% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.75 (avg: 2).